Akebia Therapeutics, Inc. (AKBA)
NASDAQ: AKBA · Real-Time Price · USD
1.560
+0.090 (6.12%)
At close: Apr 14, 2026, 4:00 PM EDT
1.550
-0.010 (-0.64%)
After-hours: Apr 14, 2026, 7:53 PM EDT
Akebia Therapeutics Employees
Akebia Therapeutics had 194 employees as of December 31, 2025. The number of employees increased by 13 or 7.18% compared to the previous year.
Employees
194
Change (1Y)
13
Growth (1Y)
7.18%
Revenue / Employee
$1,217,505
Profits / Employee
-$27,552
Market Cap
417.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 194 | 13 | 7.18% | 194 | 0 |
| Dec 31, 2024 | 181 | 14 | 8.38% | 181 | 0 |
| Dec 31, 2023 | 167 | -38 | -18.54% | 167 | 0 |
| Dec 31, 2022 | 205 | -221 | -51.88% | 204 | 1 |
| Dec 31, 2021 | 426 | 46 | 12.11% | 426 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Evolus | 334 |
| Esperion Therapeutics | 294 |
| Anika Therapeutics | 235 |
| Aquestive Therapeutics | 147 |
AKBA News
- 1 day ago - Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090 - GlobeNewsWire
- 7 days ago - Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium - GlobeNewsWire
- 12 days ago - Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors - GlobeNewsWire
- 26 days ago - Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - GlobeNewsWire
- 6 weeks ago - Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights - GlobeNewsWire
- 7 weeks ago - Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights - GlobeNewsWire